1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hepatitis C Therapies: World Industry, R&D and Market Forecasts 2015-2025

Report Details
Hepatitis C treatments – your guide to medical needs, R&D trends and future drug revenues
Discover the future of treating hepatitis C virus (HCV). Now you can get sales forecasts and explore that industry’s research and development. See where the money lies from 2014. And find where that technology heads.

Visiongain’s new guide predicts those revenues to 2025 at overall world, submarket, product and national level. Its purpose is to help you stay ahead in data, news and analysis on those therapies. It examines medical, technological and commercial potentials and opportunities.

Can that that large, profitable market sustain revenue growth? Please read on to explore HCV medicines and their producers, seeing how high that industry’s sales can go.

Forecasts and other analyses to help your research, knowledge and influence
Avoid struggles to find business information on that viral infection. Instead discover what’s happening in technology and demand for therapy. With our investigation you can make your research, appraisals and commercial decisions on hepatitis C treatments quicker and easier.
- Who is the company with the highest expected revenue from 2015 to 2025?
- What technologies give the most promising candidates for new drugs?
- Where lie the best geographical opportunities for selling those antivirals?
- Why will the HCV drug market expand, and what limits its sales growth?
- When will that industry achieve fastest expansion and peak revenues?
- How will companies overcome challenges in serving regulators, patients and payers?

Besides sales predictions to 2025, our study presents recent results, growth rates, market shares and discussions. You get 69 tables, 53 charts and two interviews with authorities.

Forecasting of the world HCV therapy market and its segments
Our report predicts overall world revenue to 2025 for those anti-infective drugs. There you also find individual revenue predictions to 2025 for two submarkets at world level:
- Oral antiviral agents
- Interferons for treating that disorder.

For treating that infectious disease, especially of the liver, discover how competition and technological advances shape the industry. So benefit your reputation for commercial knowledge. And find where the most money and best prospects for commercial growth exist.

Also assess leading pharmaceutical brands for tackling those chronic infections.

Forecasts for HCV medicines – see potentials for top brands
How will six leading and three emerging drugs perform to 2025 at world level? Our study forecasts individual revenues of nine agents:
- Sovaldi (sofosbuvir)
- Olysio (simeprevir)
- Pegasys (peginterferon alfa-2a)
- Incivek and related brands (telaprevir)
- PegIntron (peginterferon alfa-2b)
- Victrelis (boceprevir)
- Harvoni (ledipasvir and sofosbuvir)
- Daklinza (daclatasvir)
- Sunvepra (asunaprevir).

Those analyses show you how high sales can go. There find products and years with highest predicted expansion and revenues. You hear what’s happening. And you deepen your understanding of trends, competition, challenges and opportunities.

In that work you also find national revenue predictions.

Healthcare in regional markets – what outlooks for that business?
Our investigation also shows you individual revenue forecasts to 2025 for 11 countries:
- United States (US)
- Japan
- Germany, France, UK, Italy and Spain (EU5 group)
- Brazil, Russia, India and China (BRIC nations).

There you find countries with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.

And how do changes, challenges and technological advances affect that industry and market?

Forces, events and issues – developments influencing those antiviral treatments

Table Of Contents

Hepatitis C Therapies: World Industry, RandD and Market Forecasts 2015-2025
Table of Contents
1. Report Overview
1.1 Overview of the World Market for Hepatitis C Therapies
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by this Analysis
1.5 Who is this Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain

2. Introduction to Hepatitis C Therapies
2.1 A Brief History of Hepatitis C and Treatments
2.1.1 Genotypes
2.1.2 Symptoms: Acute and Chronic Hepatitis C
2.1.3 Diagnosing Hepatitis C: The Asymptomatic Nature
2.1.4 Risk Factors for Hepatitis C
2.2 Incidence and Prevalence Patterns
2.3 Hepatitis C: Treatment and Prevention
2.3.1 Antivirals: Inhibiting Virus Replication
2.3.1.1 Protease Inhibitors
2.3.1.2 Polymerase Inhibitors
2.3.1.3 NS5A Replication Complex Inhibitors
2.3.2 Interferons: Dual Mode of Action
2.3.2.1 Combination Therapy: Treatment with Interferons and Antivirals
2.3.2.2 Interferon-Free Regimens
2.3.3 Hepatitis C and the Need for a Vaccine

3. The World Hepatitis C Therapies Market, 2015-2025
3.1 Hepatitis C Therapies Market, 2013 and 2014
3.2 The Hepatitis C Therapies Market: Revenue Forecast, 2014-2025
3.2.1 Rising Awareness and Screening: Expanding Treatment Population
3.2.2 Generic Competition in the Hepatitis C Therapies Market
3.2.3 Biosimilar Interferons
3.2.4 Direct-Acting Antivirals (DAAs): A Change in Therapeutic Landscape
3.3 Oral Antivirals Submarket
3.3.1 Oral Antivirals Submarket: Revenue Forecast, 2014-2025
3.3.2 A Strong Developmental Pipeline to Drive Market Growth
3.3.3 All-Oral Treatments for Hepatitis C: Improving Tolerability
3.4 Interferons Submarket
3.4.1 Standard of Care for Hepatitis C
3.4.2 Drawbacks to Interferon Therapy
3.4.3 Declining Revenues 2008-2013
3.4.4 Interferons Submarket: Revenue Forecast, 2014-2025
3.4.5 Next Generation Interferons: A Potential Advance or Lateral Move?
3.5 Hepatitis C Vaccines Submarket
3.6 Hepatitis C Therapies: Submarket Shares 2013, 2019 and 2025

4. Leading National Hepatitis C Markets, 2015-2025
4.1 Global Prevalence of Hepatitis C, 2013
4.1.1 The Importance of Asia
4.2 Hepatitis C Therapies Market: Regional Breakdown, 2013
4.3 Hepatitis C Therapies Market: Regional Forecast, 2014-2025
4.4 The US
4.4.1 Population Movement and Hepatitis C
4.4.2 The Affordable Care Act and Hepatitis C
4.4.3 Increased Screening towards Target Population
4.4.4 The US Revenue Forecast, 2014-2025
4.5 Leading EU Markets for Hepatitis C Therapies
4.5.1 Regional Prevalence
4.5.2 EU5 Market, 2013
4.5.3 EU5: Revenue Forecasts, 2014-2025
4.5.4 Italy: Revenue Forecast, 2014-2025
4.5.5 Spain: Revenue Forecast, 2014-2025
4.5.6 Germany: Revenue Forecast, 2014-2025
4.5.7 UK: Revenue Forecast, 2014-2025
4.5.8 France: Revenue Forecast, 2014-2025
4.6 Hepatitis C in Asia
4.7 China
4.7.1 Decline in Incidence of Hepatitis C
4.7.2 Rising Middle Class
4.7.3 Hepatitis C Outbreaks
4.7.4 Domestic Drug and Vaccine Development
4.7.5 China: Revenue Forecast, 2014-2025
4.8 Japan
4.8.1 Hepatitis C in Japan
4.8.2 Japan: Revenue Forecast, 2014-2025
4.9 India
4.9.1 Low Awareness Rates
4.9.2 India: Revenue Forecast, 2014-2025
4.10 Russia
4.10.1 Low Treatment Rate and High Drug Costs Limiting Market
4.10.2 Adverse Impact of Western Sanctions on Russian Pharma Market
4.10.3 Russia: Revenue Forecast, 2014-2025
4.11 Brazil
4.11.1Current Disease Prevalence
4.11.2 Brazil: Revenue Forecast, 2014-2025

5. Leading Hepatitis C Therapies, Market Prospects to 2025
5.1 Leading Hepatitis C Therapies, 2014-2025
5.2 Sovaldi (Gilead Sciences)
5.2.1 Recent Revenue Analysis
5.2.2 Gilead Licenses Generic Substitute for Sovaldi for Developing Countries
5.2.3 Sovaldi Revenue Forecast, 2014-2025
5.3 Olysio (Janssen/Medivir)
5.3.1 Recent Revenue Analysis
5.3.2 Combination Regimen of Sovaldi and Olysio
5.3.3 Olysio Revenue Forecast, 2014-2025
5.4 Pegasys (Roche)
5.4.1 Recent Revenue Analysis
5.4.2 Label Expansions and Lifecycle Management Strategies
5.4.3 Pegasys Revenue Forecast, 2014-2025
5.5 Incivek (Vertex/Janssen (JandJ)/Mitsubishi Tanabe)
5.5.1 Recent Revenue Analysis
5.5.2 Targeting HCV/HIV Co-Infected Patients
5.5.3 Pipeline Competition May Affect Revenues
5.5.4 Incivek Revenue Forecast, 2014-2025
5.6 PegIntron (Merck and Co.)
5.6.1 Recent Revenue Analysis
5.6.2 Competition from Interferon Biosimilars
5.6.3 Enhancing Drug Life Cycle
5.6.4 PegIntron Revenue Forecast, 2014-2025
5.7 Victrelis (Merck and Co.)
5.7.1 Recent Revenue Analysis
5.7.2 Roche Collaboration
5.7.3 Product Differentiation
5.7.4 Victrelis Revenue Forecast, 2014-2025
5.8 Harvoni (Gilead Sciences)
5.8.1 Gilead-AbbVie Dispute over Ledipasvir/Sofosbuvir Patents
5.8.2Harvoni Revenue Forecast, 2014-2025
5.9 Daklinza (Bristol-Myers Squibb)
5.9.1 Daklinza Revenue Forecast, 2014-2025
5.10 Sunvepra (Bristol-Myers Squibb)
5.10.1 Sunvepra: Synergistic Effect with Daklinza
5.10.2 Sunvepra Revenue Forecast, 2014-2025

6. Hepatitis C Therapies Market: Leading RandD Pipeline Candidates, 2014
6.1 Introduction to Hepatitis C Therapy Candidates
6.2 Protease Inhibitors Pipeline
6.2.1 Vaniprevir (Merck and Co.): Patent Security through 2027
6.2.2 MK-5172 and MK-8742 (Merck and Co.): Phase III
6.2.3 Paritaprevir (formerly ABT-450) (AbbVie): Fast-Tracked into Phase III
6.2.4 Sovaprevir (Achillion Pharmaceuticals): Playing Catch Up
6.2.5 ACH-2684 (Achillion Pharmaceuticals)
6.2.6 Danoprevir (Roche): Testing Out Combination Regimens
6.2.7 Lomibuvir (Vertex Pharmaceuticals)
6.2.8 ABT-493 (AbbVie)
6.2.9 Vedroprevir (Gilead Sciences)
6.2.10 GS-9857 (Gilead Sciences)
6.3 Polymerase Inhibitors Pipeline
6.3.1 ACH-2928 (Achillion Pharmaceuticals)
6.3.2 BMS-791325 (Bristol-Myers Squibb): Phase II
6.3.3 TMC-647055 (Janssen): Phase II
6.3.4 Mercitabine (Roche/Pharmasset): Broad Spectrum Treatment
6.3.5 Setrobuvir (Roche): Non-Nucleoside Inhibitor
6.3.6 VX-135 (Vertex Pharmaceuticals): Interferon- and Ribavirin-Free Regimens
6.3.7 GS-9669 (Gilead Sciences)
6.3.8 PPI-383 (Presidio Pharmaceuticals)
6.4 NS5A Inhibitors Pipeline
6.4.1 ABT-530 (AbbVie)
6.4.2 Samatisvir (Merck and Co.): Acquired from Idenix
6.4.3 GS-5816 (Gilead Sciences)
6.4.4 PPI-668 (Presidio Pharmaceuticals)
6.5 Interferon Pipeline
6.5.1 Locteron (Biolex): Controlled Release Formulation
6.5.2 Peginterferon Lambda-1a (Bristol-Myers Squibb): Improved Side Effects Profile
6.6 Novel Inhibitors
6.6.1 SCY-635 (SCYNEXIS)
6.6.2 Miraversen (Santaris)
6.6.3 GS-9620 (Gilead Sciences)
6.6.4 RG-101 (Regulus Therapeutics)
6.7 Hepatitis C Pipeline Candidates on Hold or Discontinued, 2014
6.7.1 Alisporivir (Novartis/Debiopharm): Advanced Cyclophin Inhibitor
6.7.2 INX-189 (Bristol-Myers Squibb): Cardiovascular Effects May Halt Development
6.7.3 Idenix Developments Terminated: IDX-189 and IDX-19368
6.7.4 Deleobuvir (Boehringer Ingelheim): Development Discontinued
6.7.5 Faldaprevir (Boehringer Ingelheim): Exiting the Hepatitis C Market
6.8 Leading Hepatitis C Vaccine Pipeline Candidates, 2014
6.8.1 ChronVac-C (ChronTech Pharma/Inovio Pharmaceuticals): Therapeutic Vaccine in Phase II Trials
6.8.2 GI-5005 (GlobeImmune): Yeast-Based Hepatitis C Vaccine
6.8.3 INO-8000 HCV (Inovio Pharmaceuticals): Therapeutic Vaccine in Phase I Trials
6.8.4 Okairos Inc.: Prophylactic and Therapeutic Vaccine Candidates

7. Leading Companies in the Hepatitis C Therapies Market
7.1 Leading Market Players, 2013 and 2014
7.2 Gilead Sciences
7.2.1 Product Overview and Performance. 2013 and 2014
7.2.2 Recent Developments: Gilead Sciences Acquires Pharmasset
7.2.3 Hepatitis Pipeline: Strong and Diverse
7.2.4 Future Outlook: Strongest Pipeline than Any Other Company
7.3 Johnson and Johnson (Janssen Pharmaceuticals)
7.3.1 Product Overview and Performance, 2013 and 2014
7.3.2 Recent Developments: Acquisition of Alios BioPharma
7.3.3 Hepatitis Pipeline
7.3.4 Future Outlook: Combination Regimens with Olysio
7.4 Roche
7.4.1 Product Overview and Performance. 2013 and 2014
7.4.2 Recent Developments: Partnership with Anadys
7.4.3 Hepatitis Pipeline
7.4.4 Future Outlook: Slowing Demand May Affect Market Dominance
7.5 Bristol-Myers Squibb
7.5.1 Product Overview and Performance. 2013 and 2014
7.5.2 Recent Developments: Strengthening Product Pipeline through Acquisitions
7.5.2.1 Bristol-Myers Squibb Acquires Inhibitex
7.5.3 Hepatitis Pipeline: Strong Future Position in Hepatitis C
7.5.4 Future Outlook: Market Set For Intense Competition
7.6 Merck and Co.
7.6.1 Product Overview and Performance. 2013 and 2014
7.6.2 Recent Developments: Merck and Co. Acquires Idenix
7.6.3 Hepatitis Pipeline
7.6.4 Future Outlook: Company Pins Hopes on Launch of Pipeline Therapies
7.7 Leading Hepatitis C Pipeline Companies, 2014
7.7.1 Gilead Sciences
7.7.2 Merck and Co.
7.7.3 AbbVie (Formerly Abbott Laboratories): New Venture into Hepatitis C
7.7.4 Achillion Pharmaceuticals: Next Target for Acquisition
7.7.4.1 Achillion and Gilead

8. Hepatitis C Therapies Market: Industry Trends, 2015-2025
8.1 Strengths and Weaknesses in the Hepatitis C Therapies Market, 2014-2025
8.1.1 Interferon Therapy Has Drawbacks
8.1.2 Genotype 1: A Common but Difficult to Treat Form of Hepatitis C
8.2 Opportunities and Threats in the Hepatitis C Therapies Market, 2014-2025
8.2.1 Hepatitis Screening and Diagnosis
8.2.2 Raising Awareness and Overcoming Social Stigma
8.2.3 Personalised Therapy
8.2.4 HIV Co-Infection
8.2.5 Asia
8.3 STEP Analysis of The World Hepatitis C Therapies Market, 2014-2025
8.3.1 Social Development
8.3.1.1 Social Implications in China
8.3.2 Technological Advances
8.3.3 Economic Pressures
8.3.4 Political Issues
8.4 Hepatitis C Vaccines
8.5 Oral Direct-Acting Antivirals
8.5.1 Nucleoside and Non-Nucleoside Polymerase Inhibitors
8.5.2 Combining Protease and Polymerase Inhibitors
8.5.3 The Need for Ribavirin
8.5.4 Twelve-Week Treatment Target
8.6 Pharmaceutical Investment in Hepatitis C
8.6.1 Licensing and Partnering Deals
8.6.2 Acquisitions in Hepatitis C
8.6.3 Other Companies of Note for Hepatitis Treatment Developments

9. Research Interviews
9.1 Expert Interview 1: Authority from a Company in the Industry (Views Provided Anonymously)
9.1.1 The Hepatitis C Therapies Market Landscape
9.1.2 Interferon Therapies
9.1.3 The Future Hepatitis C Therapies Market
9.2 Interview with Susan Simon, President of the Hepatitis C Association
9.2.1 Barriers to Treatment
9.2.2 Changes to Treatment in the Past Decade and Coming Years
9.2.3 Support and Awareness for Hepatitis C

10. Conclusions
10.1 State of The Hepatitis Therapies Market, 2013 and 2014
10.2 Growth in The Hepatitis Therapies Market, 2014-2025
10.2.1 Rise of Direct-Acting Antivirals in Hepatitis C
10.2.2 Asia as a Hepatitis C Therapies Market
10.3 Concluding Remarks


List of Tables
Table 1.1 Submarket Forecasts of Hepatitis C Therapies, 2013-2019
Table 1.2 Submarket Forecasts of Hepatitis C Therapies, 2019-2025
Table 1.3 Foreign Currency Exchange Rates: Average Exchange Rate to USD
Table 2.1 Global Pattern of Hepatitis C Genotypes and Subtypes, 2014
Table 2.2 Approved Antiviral Subtypes for Hepatitis C, 2014
Table 3.1 Hepatitis C Therapies Market ($bn and %) by Sector, 2013
Table 3.2 Hepatitis C Therapies Market ($bn and %) by Sector, 2014
Table 3.3 Hepatitis C Therapies Market: Overall Market Forecast of Currently Approved Drugs and Predicted Approvals ($bn), 2014-2025
Table 3.4 Hepatitis C Therapies Market: Revenue Forecasts by Segment ($bn), 2014-2025
Table 3.5 Selected Biosimilar Interferon Alpha Therapies Approved in Emerging National Markets, 2013
Table 3.6 Leading Hepatitis C Antivirals: Revenue Shares by Drug ($bn and %), 2013
Table 3.7 Oral Antivirals Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.8 Interferons Submarket: Revenue ($bn) and Market Share (%) by Drug, 2013
Table 3.9 Interferons Submarket: Revenue Forecast ($bn), 2014-2025
Table 3.10 Hepatitis C Submarket Shares (%), 2013, 2019 and 2025
Table 4.1 Global Prevalence of Chronic Hepatitis C, 2013
Table 4.2 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Region, 2013
Table 4.3 Hepatitis C Therapies: Overall Market and Revenue Forecasts ($bn) by Region, 2014-2025
Table 4.4 US Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.5 EU5 Hepatitis C Therapies: Revenue ($bn), EU5 Market Share (%) and Global Market Share (%) by Country, 2013
Table 4.6 EU5 Hepatitis C Therapies Market: Overall Revenue Forecast ($bn), 2014-2025
Table 4.7 Italian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.8 Spanish Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.9 German Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.10 UK Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.11 French Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.12 Chinese Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.13 Japanese Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.14 Indian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.15 Russian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 4.16 Brazilian Hepatitis C Therapies: Forecast ($bn), 2014-2025
Table 5.1 Selected Leading Hepatitis C Therapies ($bn and %), 2013
Table 5.2 Sovaldi: Key Facts, 2014
Table 5.3 Sovaldi: Revenue ($bn) by Region, Q1-Q3, 2014
Table 5.4 Sovaldi: Revenue Forecast ($bn), 2014-2025
Table 5.5 Olysio: Key Facts, 2014
Table 5.6 Olysio: Revenue ($bn) by Region, Q1-Q3, 2014
Table 5.7 Olysio: Revenue Forecast ($bn), 2014-2025
Table 5.8 Pegasys: Key Facts, 2014
Table 5.9 Pegasys: Revenue Forecast ($bn), 2014-2025
Table 5.10 Incivek: Key Facts, 2014
Table 5.11 Incivek: Revenue ($bn) and Market Share (%) by Region, 2013
Table 5.12 Incivek: Revenue Forecast ($bn), 2014-2025
Table 5.13 PegIntron: Key Facts, 2014
Table 5.14 PegIntron: Revenue Forecast ($bn), 2014-2025
Table 5.15 Victrelis: Key Facts, 2014
Table 5.16 Victrelis: Revenue Forecast ($bn), 2014-2025
Table 5.17 Harvoni: Key Facts, 2014
Table 5.18 Harvoni: Revenue Forecast ($bn), 2014-2025
Table 5.19 Daklinza: Key Facts, 2014
Table 5.20 Daklinza: Revenue Forecast ($bn), 2014-2025
Table 5.21 Sunvepra: Key Facts, 2014
Table 5.22 Sunvepra: Revenue Forecast ($bn), 2014-2025
Table 6.1 Selected Hepatitis C Pipeline Candidates in Phase II and III, 2014
Table 7.1 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Company, 2013
Table 7.2 Hepatitis C Therapies: Revenue ($bn) and Market Share (%) by Company, 2014
Table 7.3 Gilead Sciences: Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013
Table 7.4 Gilead Sciences: Hepatitis C Pipeline, 2014
Table 7.5 Roche: Hepatitis C Pipeline, 2014
Table 7.6 Pegasys: Revenue ($bn) and Market Share (%), 2013, 2019 and 2025
Table 7.7 Bristol-Myers Squibb: Hepatitis Pipeline, 2014
Table 7.8 Merck and Co.: Pharmaceutical Revenue ($bn) and Revenue Share (%) by Therapeutic Area, 2013
Table 7.9 Gilead Sciences: Hepatitis C All-Oral Regimens, 2014
Table 7.10 Merck and Co.: Hepatitis C All-Oral Regimens, 2014
Table 7.11 AbbVie: Hepatitis C All-Oral Regimens, 2014
Table 7.12 Achillion Pharmaceuticals: Hepatitis C All-Oral Regimens, 2014
Table 8.1 Hepatitis C Therapies Market: Strengths and Weaknesses, 2014
Table 8.2 Hepatitis C Therapies Market: Opportunities and Threats, 2014-2025
Table 8.3 Liver Cancer: Deaths by Region, 2012
Table 8.4 Selected All-Oral Hepatitis C Regimens in Development, 2014
Table 10.1 Hepatitis C Therapies: Revenue ($bn) by Drug and Segment, 2013, 2019 and 2025
Table 10.2 Leading Hepatitis Treatments: Patent Expiries and Peak Revenues ($bn)


List of Figures
Figure 1.1 Hepatitis C Market Segmentation, 2014
Figure 2.1 Brief History of Hepatitis, 1947-2014
Figure 3.1 Hepatitis C Therapies Market by Segment (%), 2013
Figure 3.2 Hepatitis C Therapies Market by Segment (%), 2014
Figure 3.3 Hepatitis C Therapies Market: Overall Market Forecast ($bn), 2014-2025
Figure 3.4 Global Hepatitis C Therapies Market: Drivers and Restraints, 2014-2025
Figure 3.5 Leading Hepatitis C Antivirals Submarket Share (%), 2013
Figure 3.6 Oral Antivirals Market: Drivers and Restraints, 2014-2025
Figure 3.7 Oral Antivirals Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.8 Interferons Submarket: Market Share (%) by Drug, 2013
Figure 3.9 Interferons Submarket: Revenue Forecast ($bn), 2014-2025
Figure 3.10 Interferons Submarket: Drivers and Restraints, 2014-2025
Figure 3.11 Hepatitis C Submarket Shares ($bn), 2013, 2019 and 2025
Figure 4.1 Chronic Hepatitis C: Global Prevalence (%) by Region, 2013
Figure 4.2 Hepatitis C Therapies: Market Share (%) by Region, 2013
Figure 4.3 Hepatitis C Therapies: Market Share (%) by Region, 2019
Figure 4.4 Hepatitis C Therapies: Market Share (%) by Region, 2025
Figure 4.5 US Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.6 EU5 Hepatitis C Therapies: Market Share (%) by Country, 2013
Figure 4.7 EU5 Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.8 Italian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.9 Spanish Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.10 German Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.11 UK Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.12 French Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.13 Chinese Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.14 Japanese Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.15 Indian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.16 Russian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 4.17 Brazilian Hepatitis C Therapies: Submarket Forecast ($bn), 2014-2025
Figure 5.1 Sovaldi: Revenue ($bn) by Region, Q1-Q3, 2014
Figure 5.2 Sovaldi: Revenue Forecast ($bn), 2014-2025
Figure 5.3 Olysio: Recent Revenue ($bn), Q1-Q3, 2014
Figure 5.4 Olysio: Revenue Forecast ($bn), 2014-2025
Figure 5.5 Pegasys: Revenue ($bn), 2011-2014
Figure 5.6 Pegasys: Revenue Forecast ($bn), 2014-2025
Figure 5.7 Incivek: Market Share (%) by Region, 2013
Figure 5.8 Incivek: Revenue Forecast ($bn), 2014-2025
Figure 5.9 PegIntron: Recent Revenue ($bn), 2011-2014
Figure 5.10 PegIntron: Revenue Forecast ($bn), 2014-2025
Figure 5.11 Victrelis: Recent Revenue ($bn), 2011-2014
Figure 5.12 Victrelis: Revenue Forecast ($bn), 2014-2025
Figure 5.13 Harvoni: Revenue Forecast ($bn), 2014-2025
Figure 5.14 Daklinza: Revenue Forecast ($bn), 2014-2025
Figure 5.15 Sunvepra: Revenue Forecast ($bn), 2014-2025
Figure 7.1 Hepatitis C Therapies: Market Share (%) by Company, 2013
Figure 7.2 Hepatitis C Therapies: Market Share (%) by Company, 2014
Figure 7.3 Gilead Sciences: Revenue Share (%) by Therapeutic Area, 2013
Figure 7.4 Johnson and Johnson: Key Events in the Hepatitis C Drug Market, 2011-2014
Figure 7.5 Pegasys: Revenue ($bn), 2013, 2019 and 2025
Figure 7.6 Merck and Co.: Revenue Share (%) by Therapeutic Area, 2013
Figure 8.1 Liver Cancer: Deaths by Region, 2012
Figure 10.1 Hepatitis C Therapies: Revenue ($bn) by Segment, 2013, 2019 and 2025

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Benzyl Alcohol Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • August 2016
  • by Transparency Market Research

Benzyl alcohol is an aromatic alcohol, which is metabolized into benzoic acid inthe human body. Benzyl alcohol is manufactured by hydrolysis of benzyl chloride in the presence of soda ash through the toluene ...

Asia-Pacific Animal Health Market - Forecast to 2021

Asia-Pacific Animal Health Market - Forecast to 2021

  • $ 5650
  • Industry report
  • October 2016
  • by MarketsandMarkets

The APAC animal health market is estimated to grow at a CAGR of 5.7% during the forecast period, to reach USD 20.25 billion by 2021 from USD 15.32 billion in 2016. Growth in this market can primarily be ...

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

Silver Sulfadiazine Market: By Application (Wound Care, Burn Care, Skin Care, UTIs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Silver sulfadiazine is an antibacterial drug used for making personal care products. Silver sulfadiazine is listed as the essential medicines by World Health Organization and is widely used as an antibiotic ...

Global Feed Antibiotics Market

October 2016 $ 4250

Download Unlimited Documents from Trusted Public Sources

Anti-Infective Market in Ghana

  • December 2016
    10 pages
  • Anti-Infective  

  • Ghana  

View report >

Anti-Infective Market in Canada

  • November 2016
    215 pages
  • Anti-Infective  

    Civil Protectio...  

    Environment  

  • Canada  

    North America  

View report >

Therapy Market in India, Monthly Update

  • November 2016
    37 pages
  • Therapy  

View report >

Anti-infective Market

19 days ago

Related Market Segments :

Anti-Infective

ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.